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ABSTRACT 
Sweat test or pilocarpine iontophoresis test is the existing method for diagnosis of cystic 
fibrosis that is recommended to perform at 48 hours after birth. However, the current method is 
painful, with several side effects such as full thickness skin burn, skin rash, erythema etc. 
Therefore, the purpose of this study is to develop a pilocarpine topical formulation which can 
stimulate sweat secretion when applied on skin without iontophoresis. Several formulations with 
Transcutol®, polyethylene glycol 400 (PEG 400), Polyethylene glycol 200 (PEG 200), menthol 
and salicylic acid (SA) each at varying concentrations were screened as penetration enhancers. In 
vitro penetration test (IVPT) was performed on these formulations to compare the influence of 
these ingredients on the penetration of pilocarpine. The results from the preliminary studies 
indicate that the formulation with SA showed better penetration into porcine skin after both 10 
minutes (120.29 ± 27.54 µg/cm2) and 40 minutes (158.97 ± 20.15 µg/cm2) compared to others. 
Based on the preliminary studies, the lead formulation was decided to have pilocarpine nitrate, 
ethanol and water as solvents, salicylic acid as penetration enhancer, PEG 200 as a hydrating 
agent to minimize any dehydration due to ethanol, menthol as a cooling agent and sodium 
hydroxide as a pH modifier. The penetration of pilocarpine nitrate on application of lead 
formulation into the porcine skin was compared to that of iontophoresis technique by both IVPT 
as well as tape stripping techniques. The IVPT results indicate that total amount of pilocarpine 
nitrate recovered from skin with passive formulation (152.04 ± 52.23 µg/cm2 after 10 min, 
210.27 ± 53.72 µg/cm2 after 40 min) is higher than that of iontophoresis with pilocarpine 
solution (97.05 ± 27.93 µg/cm2 after 10 min, 140.56 ± 88.66 µg/cm2 after 40 min) at both 10 
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and 40 minutes. The tape stripping data showed a correlation with the IVPT results. The amount 
of pilocarpine recovered from the tape strips used in the lead formulation (78.46 µg/mg at 10 min 
and 53.32 µg/mg at 40 min) was significantly higher than the pilocarpine recovered from tape 
strips used for iontophoresis (13.32 µg/mg at 10 minute and 7.38 µg/mg at 40 minutes). The lead 
formulation was also investigated for its effectiveness by a clinical study on 20 human volunteers 
to determine if the developed formulation was efficient enough to stimulate the sweat 
production. The average amount of the sweat secreted due to passive formulation was found to 
be 77.28 ± 18.97 mg when applied on an area of 38.46 cm2. Based on these results, it can be 
concluded that the passive formulation was successful in delivering pilocarpine and to stimulate 
sweat secretion which can be a compliant alternative technique to iontophoresis.
 iv 
 
DEDICATION 
I dedicate my thesis to my wonderful family. I am grateful to my parents, Dr. Rouf Sarder 
and Dr. Habiba Khatoon, who provide unconditional support throughout this master’s program. I 
am also grateful to my younger brother Dr.  Mahmud Mohammad Sarder for his immense help 
and continuous emotional support during this program. I am especially thankful to my loving 
husband, Tanzil Rahman, for encouraging me and giving me constant motivation throughout the 
program. 
 v 
 LIST OF ABBREVIATIONS 
 
CF: Cystic Fibrosis 
CFTR: Cystic Fibrosis Transmembrane Conductance Regulator 
EPI: Exocrine Pancreatic Insufficiency 
ASL: Airway Surface Liquid 
Tr: Transcutol 
P200: Polyethylene glycol 200 
P400: Polyethylene glycol 400 
M: Menthol 
SA: Salicylic acid 
API: Active Pharmaceutical Ingredient 
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 1 
INTRODUCTION 
 
Disease Overview 
Cystic fibrosis (CF) is a progressive genetic disease that is inherited in autosomal recessive 
manner (1). According to the Cystic Fibrosis Foundation Patient Registry, more than 30,000 
people have cystic fibrosis in the United States and more than 70,000 people worldwide. Each 
year, approximately 1,000 new cases of CF are diagnosed and more than 75 percent of patient with 
CF are diagnosed by age two (2). It is usually manifested as persistent lung infection, aquagenic 
wrinkling of palm as shown in figure 1 (3), exocrine pancreatic insufficiency and excessive amount 
of salt in the sweat. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a 
membrane protein and chloride channel that is found in sebaceous and exocrine gland (5), lung, 
liver, pancreas and it is encoded by CFTR gene (5, 6). CFTR gene is located at chromosome 7 (6) 
and genetic mutation on chromosome 7 results in cystic fibrosis. In healthy individual, this CFTR 
chloride channel regulates the transport of sodium, chloride and bicarbonate ions. This genetic 
mutation results in abnormality in production and function of protein CFTR that leads to reduced 
transport of sodium chloride, defect in reabsorbing chloride of sweat duct (7, 8) and excretion of 
large amount of sweat electrolytes (9). 
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Figure 1: Aquagenic wrinkling of palm 
                                        
Sweat gland 
CFTR is highly expressed in sebaceous gland. In eccrine glands and ducts, CFTR is located 
in apical membrane of the cells lining the sweat duct. Sweat gland is located in hypodermis of the 
skin and it helps to maintain the body temperature by releasing the sweat from hypodermis onto 
the skin surface. Sweat consists of water and salt (Na+ and Cl-), generated by sweat gland and is 
carried through the sweat duct onto the skin surface. In healthy individuals, salt and water are 
reabsorbed into the skin. However, in cystic fibrosis patients, defective CFTR protein does not 
allow the sodium and chloride ions to reabsorb into the cells lining the sweat duct which results in 
the deposition of salt in the skin (10,11). Salty skin as shown in figure 2 (12) is one of the most 
common symptoms of cystic fibrosis and it causes severe itchiness and redness of the skin (12). 
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      Figure 2: Salty skin in patient of cystic fibrosis 
 
Lungs 
CFTR is located in the epithelial cells inside the lung. Lung alveoli are lined up by the 
alveolar cells that produces mucus. This thin mucus layer or airway surface liquid (ASL) coats the 
airway and protects the airway by trapping the bacteria and foreign particle.  Moreover, constant 
movement of cilia wipes the foreign particle up and out of the airways. In cystic fibrosis individual, 
defected CFTR protein does not allow the chloride ions to reach the chloride channel and it also 
increases the transport of sodium along with the water out of the surface liquid (13). As a result, 
the ASL becomes thick and thick layer of mucus hamper the function of cilia that leads to 
entrapment of bacteria within the airway and chronic infection of the lung (11).  
Pancreas and the Gastrointestinal (GI) tract 
Cystic fibrosis is one of the most common cause of exocrine pancreatic insufficiency (EPI). 
In cystic fibrosis, the thick mucus layer clogs the pancreas and blocks the pancreatic enzyme from 
entering the small intestine that leads to EPI (14). As the pancreatic enzyme cannot enter the small 
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intestine, this affects the digestion of food particularly fat and protein leading to malnutrition (11, 
15). 
Management of Cystic Fibrosis  
There is no cure for cystic fibrosis. However, early treatment and close monitoring by the 
specialist can reduce the complications from multisystem involvement. The management of CF 
includes initial diagnosis by genetic and sweat test, prompt treatment and close follow up of the 
patient. The goal of CF treatment is to maintain the lung function, prevent the intestinal obstruction 
and to provide nutritional supplement. Frequent clearance of airway, inhalation of the 
bronchodilator and intake of oral antibiotic help to reduce the pulmonary exacerbations (16, 17).  
Inhalation of hypertonic saline increases the volume of ASL and remove thick mucus layer from 
the airway and improve the lung function (18). Cystic fibrosis patient suffering from exocrine 
pancreatic insufficiency are treated with oral pancreatic enzyme. Ivacaftor (19), lumacaftor-
ivacaftor (20) are used to improve the function of defected CFTR protein.  
Methods for diagnosis of cystic fibrosis includes sweat testing or genetic test. The sweat 
test is relatively less expensive and easily deployable in any place. The sweat test includes 
electrically mediated application of pilocarpine for inducing sweat.  
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Pharmacology of Pilocarpine     
                                         
Figure 3: Structure of Pilocarpine 
 
Pilocarpine is an alkaloid derived from the plant of genus Pilocarpus (21, 22). Pilocarpine 
is a cholinergic agonist or muscarinic receptor agonist that increases the effect of acetylcholine in 
the body. Pilocarpine is available in market as pilocarpine hydrochloride tablet (5 mg, 7.5 mg and 
10 mg). The mean elimination half-life is 0.76 hours and maximum plasma concentration (Cmax) 
is 15 ng/ml (23). It requires 1.25 hours to reach peak plasma level. For 10 mg dose, the mean 
elimination half-life is 1.35 hours, the maximum plasma concentration (Cmax) is 41 ng/ml and peak 
plasma level reaches 0.85 hours (23). Pilocarpine metabolizes to pilocarpic acid by serum esterase 
at neuronal synapse and excreted in urine (21). Pilocarpine is also available as pilocarpine nitrate 
eye drop (2.0% w/v). 
As pilocarpine is a parasympathomimetic drug that mimics the action of acetylcholine 
released by parasympathetic nervous system and acetylcholine decreases the heart rate, so 
pilocarpine increases the effect of parasympathetic nervous system and decreases the heart rate 
(24). As a muscarinic receptor agonist, pilocarpine produces vascular relaxation and conjunctival 
vasodilation (25). Pilocarpine causes contraction of ciliary muscle, that opens the trabecular 
meshwork. Opening of the meshwork accelerates the drainage of aqueous humor resulting in 
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decrease intraocular pressure (26). Therefore, pilocarpine is used to treat glaucoma. Pilocarpine 
stimulates the muscarinic receptor (M1) of myoepithelial cells that surrounds the secretory coils 
of sweat gland and cause contraction of myoepithelial cells and facilitate secretion of sweat (27, 
28). Pilocarpine (2% solution) also stimulates the salivary gland and stimulates the salivary flow 
(29). 
Side Effects of Pilocarpine 
Therapeutic dose of pilocarpine ranges from 5 mg to 10 mg orally per day. Dose of 
pilocarpine should not exceed more than 30 mg/day. Overdose leads to headache, visual 
disturbance, hallucination, sweating, abnormal heart rate, hypotension, vomiting, nausea and 
diarrhea (30). Sweating, nausea running nose, increased salivation and lacrimation, frequent urge 
to urinate may occur as side effects of pilocarpine (31). 
Physiochemical Properties of Pilocarpine nitrate 
 
Physicochemical property Value 
Molecular weight 271.273 g/mol 
Melting Point 173.5-174° C 
Log P 1.1 
pKa 1.6, 1.7 
Table 1: Physicochemical properties of pilocarpine 
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Physicochemical properties of pilocarpine are shown in table 1. Pilocarpine is soluble in water, 
alcohol and chloroform. It is sparingly soluble in ether, benzene (32). Pilocarpine is hygroscopic 
in nature (32) and sensitive to light (33). 
 
Reason to choose pilocarpine nitrate over pilocarpine hydrochloride 
Pilocarpine hydrochloride containing formulation was applied to the filter paper to check 
if the chloride ions of pilocarpine hydrochloride would interfere with chloride concentration of 
sweat. Following the application, chloride ions from pilocarpine hydrochloride solution was 
getting stuck into the filter paper and these chloride ions were detected in chloride analyzer 
which may interfere with chloride concentration of sweat during future study and the exact 
chloride concentration of sweat may not be detected by the chloride analyzer. This filter paper 
was dissolved into distilled water and that solution was run into HPLC. A sharp peak for 
pilocarpine HCL was found confirming that pilocarpine hydrochloride was getting stuck into the 
filter paper. As one of the aim of this study to measuring the chloride concentration of the sweat; 
interference of chloride ions of pilocarpine hydrochloride was not favorable for this study.  
Formulations containing pilocarpine nitrate showed no chloride ion interference with the 
chloride analyzer. Enhancers were kept same while making the formulations. So, pilocarpine 
nitrate was used as an API to make the topical formulation. 
Current Diagnostic Method of Cystic Fibrosis 
 
Sweat test or pilocarpine iontophoresis test is the current method that is used as a screening 
test for diagnosis of cystic fibrosis. The quantitative pilocarpine iontophoresis test includes the 
stimulation of sweat by iontophoresis, collection of sweat with the use of gauze, filter paper or 
macroduct coils followed by quantification of chloride in sweat (34, 35). Pilocarpine is used as a 
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diagnostic agent during this iontophoresis. In this test, a gauge of 5.1x 5.1- cm is soaked into 2 or 
3 ml of 0.2- 0.5% of pilocarpine solution and the electrodes are placed over the gauge (30). The 
current of 2.5 to 4 mA is applied on 26 cm2 area of the forearm to stimulate the sweating and the 
sweat is collected for 30 minutes (36). Then the amount of chloride concentration in sweat is 
quantified by using chloride analyzer (37).  
 
The Need for Passive Formulation as New Diagnostic Method of Cystic Fibrosis 
 
Iontophoresis method causes pain to children as the current of 2.5 to 4 mA is applied to 
deliver the pilocarpine. There are incidences of patient’s skin being burned during iontophoresis 
for sweat induction. It also has been reported to cause several side effects such as skin burn, skin 
rash, erythema etc. (38). It has been reported that a seven week old child develop four 
semicircular area of burn from the electrode during the iontophoresis. There is a report of another 
incidence where a child experienced burn from iontophoresis that produce two mm diameter of 
circular punched out lesion, that penetrate completely through all the layer of the skin (38). 
There are some other incidences such as redness of the skin, blisters with or without scaring, 
frank electrical burn that have been reported while performing the iontophoresis test on adults 
(38). Most of the time burn occurs during iontophoresis due to application of current. To avoid 
this, it was suggested to incorporate an automatic current limiter to shut down the iontophoresis 
if the current exceeds more than 1.75 mA (38). But this safety feature does not significantly 
reduce the incidence of burn (38). Hence developing a passive formulation has an advantage 
over iontophoresis. Moreover, sweat test costs between $200-$500 (39, 40, 41). 
In passive formulation method, very small amount of pilocarpine formulation (24 mg of 
pilocarpine) is applied on the skin for 10 minutes. The amount of pilocarpine that penetrates the 
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skin is negligible and may reach the systemic circulation but would not cause any toxicity or side 
effects at such minute dose. So there are absolutely no chances for any systemic side effects using 
topical pilocarpine formulation. Moreover, an adult can intake 5 mg or 7.5 mg of pilocarpine orally 
per day, but it should not exceed more than 30 mg per day (42). As per FDA, the prescribing 
dosage of pilocarpine is 5 mg or 7.5 mg per day (43). So the amount that is expected to penetrate 
the skin in 10 minutes is likely not more than a quantity that is about 1/100 th of recommended 
oral dose.   
As this screening test is commonly performed on neonates and is recommended at 48 hours 
after birth, there is a need to develop an efficient, alternative, painless method for the same. 
Therefore, the purpose of this study is to develop a pilocarpine topical formulation which will 
generate enough quantity of sweat without the use of current.  
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OBJECTIVE OF THE STUDY 
 
The objective of the present study was to develop a pilocarpine containing topical 
formulation that penetrates the skin and stimulates sweat production. The extent of perspiration 
and the concentration of chloride in sweat were estimated followed by sweat stimulation. 
Pilocarpine containing topical formulation with different enhancers were prepared and 
characterized. In vitro and clinical study were performed for the formulation. 
As a part of preliminary testing, In- vitro skin penetration of the drug was investigated on 
porcine skin using the passive pilocarpine formulation and iontophoresis technique to quantify the 
amount of drug penetrated into the skin. estimation of extent of perspiration has been performed 
on human subjects where the developed pilocarpine topical formulation is applied directly on the 
skin and the sweat stimulation. 
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MATERIALS AND METHODS 
 
Materials 
Pilocarpine nitrate (≥98.0%), Pilocarpine hydrochloride (≥98.0%), Polyethylene Glycol 
200, Polyethylene Glycol 400, Menthol, Salicylic acid (99%), Sodium chloride Gran USP-FCC, 
Coomassie brilliant blue G-250, Grade 4 qualitative filter paper Standard grade circle 70 mm 
were purchased from VWR, USA. TRANSCUTOL HP (diethylene glycol monoethyl ether) was 
obtained gift sample from Gattefosse, USA. Combined acid buffer and chloride standard (100 
mmol/l of chloride) were purchased from Nelson Jameson Inc. USA.  Adult Electrodes (3M Red 
DotTM) and adhesive tape (Transpore TM) were purchased from 3M Science, USA. Heat bandage 
(Therma Care Heatwraps) was purchased from Walmart, USA. All solvents used in the analysis 
of were of HPLC grade. The formulation that was used for clinical study, was prepared in cGMP 
lab and the ingredients of this formulation were also prepared in cGMP grade. 
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Methods 
Development of Pilocarpine Containing Topical Formulation 
 
Different enhancers and ingredients used during development of topical formulation are 
mentioned in table 2 and table 3 respectively. 
Name of Enhancers Abbreviation Mechanism of Action 
Transcutol HP (diethylene 
glycol monoethyl ether) 
Tr Improving the solubility of drug 
within stratum corneum (44) 
Polyethylene glycol 400 (PEG 
400) 
P400 Enhances the solubility of the 
drug within stratum corneum (45) 
Polyethylene glycol 200 (PEG 
200) 
P200 Enhances the solubility of the 
drug within stratum corneum (45) 
Menthol M Enhancing the hydration of 
stratum corneum lipid (46) 
Salicylic acid SA Keratolytic action (47) 
Table 2:  The list of the enhancers with mechanism of action 
 
 
Ingredients Purpose 
Pilocarpine nitrate API 
Water Solvent 
Ethanol Solvent 
Enhancers Penetration Enhancer 
Table 3: The list of ingredients used in topical formulation 
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Screening of the penetration enhancers 
 
Pilocarpine containing topical formulations were prepared with different enhancers. 
Compositions of the formulations containing individual enhancer are mentioned in table 4 
 
Formulation Enhancer 
(w/w%) 
Pilocarpine 
nitrate 
(w/w%) 
Ethanol 
(w/w%) 
Water 
(w/w%) 
Tr 5% 5% 5% 27% q.s. 
Tr 10% 10% 5% 27% q.s. 
P400 5% 5% 5% 27% q.s. 
P400 10% 10% 5% 27% q.s. 
P200 5% 5% 5% 27% q.s. 
P200 10% 10% 5% 27% q.s. 
M 2.5% 2.5% 9% 45% q.s. 
M 5% 5% 9% 45% q.s. 
SA 5% 5% 5% 59.5% q.s. 
SA 10% 10% 5% 59.5% q.s. 
Table 4: Composition of the formulations containing individual enhancer 
                 
Compositions of the formulations containing combination of enhancers are mentioned in table 5 
Formulation PG 200 
(w/w%) 
M 
(w/w%) 
SA 
(w/w%) 
Pilocarpine 
(w/w%) 
Ethanol 
(w/w%) 
Water 
(w/w%) 
P200 + M 10% 4%      -- 6% 45% q.s. 
P200 + M + SA 
(pH was adjusted 
to 4 by NaOH) 
10% 4% 10% 6% 45% q.s. 
Table 5: Composition of the formulations containing combination of enhancers 
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Five individual enhancers were used to prepare the formulation: Transcutol®, polyethylene 
glycol 400, polyethylene glycol 200, menthol and salicylic acid. For each enhancer except for 
menthol, two formulations were prepared with the enhancer concentration of 5% and 10%. 
Pilocarpine nitrate concentration was 5% for each of the solution. For menthol, two formulations 
were prepared with the enhancer concentration of 2.5% and 5% and pilocarpine nitrate 
concentration was 9% for each of the solution. Concentration of ethanol was 27% for all the 
formulations except for the one with salicylic acid and the one with menthol. For the formulation 
with SA, the ethanol concentration was 59.5% and for the formulation with menthol, it was 45%. 
Quantity sufficient water was added in all the formulations.  
Two formulations were prepared by combination of enhancers. The first formulation 
constituted PG 200 and Menthol and the second formulation comprised of PG 200, Menthol and 
Salicylic acid. The pH of the formulation was adjusted to pH 4 by adding NaOH. 
Preparation of topical formulation with pilocarpine nitrate 
 
                                                                                           Water              
 
 
 
As shown in figure 4, each of the ingredients were weighed and added to the formulation 
in sequence of ethanol, enhancer/enhancers, pilocarpine nitrate. Water was added to dissolve the 
other ingredients of formulation. The final formulations were stored in amber color glass 
containers away from light. 
 
Ethanol Pilocarpine 
nitrate 
Enhancer 
Topical 
Formulation 
Figure 4: Steps of Preparing Topical Formulation 
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HPLC Analysis 
 
Pilocarpine concentrations in the samples were quantified using a reversed phase HPLC 
method. The analysis was carried out on Waters HPLC system (Water 600 Controller, USA) 
equipped with a 600-pump unit, a 717 plus auto sampler with an injection valve with a sample 
loop of 50 µl, and a 2487 dual absorbance UV detector. The mobile phase consists of pH 3 buffer 
and methanol in the ration 90:10. pH 3 buffer is prepared using 10 mM of potassium phosphate 
solution adjusted with o-phosphoric acid. The mobile phase was filtered by using filter paper 
(Whatman, Grade 4, Qualitative circles, 0.2 micron). A flow rate of 0.6 ml/min-1 was used to elute 
pilocarpine. 30 µl of injection was eluted in a LUNA 5µ C18 (2) 250 x 4 60 mm column 
(Phenomenex, USA) and the column was maintained at 27°C. The UV detection was set at 215 
nm and the retention time of pilocarpine was 4.6 min. Water was used as a solvent for preparation 
of standard concentrations of pilocarpine and calibration curve was plotted in the range of 0.5 µg 
-10 µg. 
Drug Recovery Study 
 
Drug recovery studies were performed to validate the In vitro penetration study. 
Validation study was conducted by using three doses (13 µl/cm2, 19 µl/cm2, 25 µl/cm2). The 
effective area for this study was 0.94 cm2.  Fresh full thickness porcine skin was brought from a 
local slaughterhouse. The abdominal skin regions were taken and shaved using an electric shaver 
and subcutaneous fat was removed completely. The skin was cut into medium size rectangular 
pieces and the pieces were covered with aluminum foil. The skin was stored immediately in a 
refrigerator at 5°C for future use. Fat free full thickness skin was used (n=3) for each dose. 
Followed by application of each dose, the skin was allowed to dry for 40 minutes. After 40 
minutes of drying, each piece of skin was washed with 15 ml of water so as to remove the 
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superficial drug. Followed by washing for first time, the same piece of skin was washed again 
with another 15 ml of water to make sure that no superficial drug was present in the skin. The 
same piece of skin was placed into another vial containing 15 ml of water.  The vials were 
covered with aluminum foil and left in a bio shaker for overnight, so that the pilocarpine that has 
been penetrated into the skin gets extracted into the water. Four different extraction procedures 
were tried in order to validate the extraction procedure of pilocarpine to precipitate the protein. 
The solution was taken into 4 Eppendorf tubes of which acetonitrile was added to two of them 
and methanol into other two. The acetonitrile and methanol added solutions were either acidified 
or basified to precipitate the proteins. The Eppendorf tubes were kept for centrifugation and the 
supernatant solutions were analyzed for pilocarpine using validated HPLC method. 
 
 
 
 
 
 
                              
 
 
In vitro penetration study (IVPT) 
 
The IVPT was performed for screening of enhancers. The in vitro skin penetration study 
was performed using Franz diffusion cells with an effective diffusion area of 0.94 cm2. The full 
Dose (µl/cm2) % Recovery 
13 µl/cm2 91.33 ± 2.3 
19 µl/cm2 93.18 ± 3.1 
25 µl/cm2 98.46 ± 2.8 
Table 6: Drug recovery for different doses 
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thickness skin was sandwiched between the donor and receiver compartment with the stratum 
corneum side facing the donor compartment. 
17 µl/cm2 of developed topical formulation was loaded into 0.94 cm2 area of donor 
compartment. There were total twelve topical pilocarpine formulations with different enhancers of 
different concentrations. IVPT was performed on the formulation with each enhancer of two 
different concentration.  
For each solution, there were 6 trials. For first 3 trials, duration of study were 10 minutes. 
Full thickness skin was collected at 10th minute of time point. The duration of study was 40 
minutes for last 3 trials and full thickness skin was washed after 40 minute. Each skin that was 
collected form trials was washed with distilled water in a beaker, cut into small pieces and 
immersed into 15 ml of water. The vials were covered with aluminum foil and left in a bio shaker 
for overnight, so that the pilocarpine formulation that has been penetrated into the superficial skin 
extracts into the water. 300 µl of solution was collected from each vial into the Eppendorf tube 
and 600 µl of basified Acetonitrile was added to each of the tube. The Eppendorf tubes were kept 
for centrifugation and the supernatant solutions were analyzed for pilocarpine using validated 
HPLC method.    
Followed by the IVPT with individual enhancer, IVPT was performed for the second time 
with the two formulations with combination of enhancers by following the same procedures as 
mentioned above. 
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Drug Retention Study 
 
IVPT with the final passive formulation and iontophoresis with 0.5% pilocarpine solution 
were performed as the part of the study. 
 
IVPT for screening of penetration enhancers  
 
Six trials were performed for final formulation. For first 3 trials, duration of study were 10 
minutes. Full thickness skin was collected at 10th minute of time point. The duration of study was 
40 minutes for last 3 trials and full thickness skin was collected at 40th minute time point. The full 
thickness skin was sandwiched between donor and receiver compartment with the stratum 
corneum side facing the donor compartment. 17 µl/cm2 of final formulation was loaded into 1.74 
cm2 area of donor compartment. Last 3 cells of 40th minute time point were placed in an incubator 
at a temperature of 40° C.  Each skin that was collected form trials was washed with distilled water 
in a beaker, cut into small pieces and immersed into 15 ml of water. The vials were covered with 
aluminum foil and left in a bio shaker for overnight, so that the pilocarpine formulation that has 
been penetrated into the superficial skin will come out into the water. 300 µl of solution was 
collected from each vial into the corresponding Eppendorf tube and 600 µl of basified Acetonitrile 
was added to each of the tube. The Eppendorf tubes were kept for centrifugation and the 
supernatant solutions were analyzed for pilocarpine using validated HPLC method.    
 
Pilocarpine Iontophoresis on Porcine Skin 
 
Iontophoresis was a control study and it was performed by using the Chattanooga IontoTM 
iontophoresis device. Six trials were performed for iontophoresis. 113 µl/cm2 of 0.5% pilocarpine 
solution was applied on 1.76 cm2 area of the full thickness porcine skin. The full thickness skin 
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was sandwiched between two 3M Red DotTM Adult Electrodes. The positive electrode was 
attached to the electrode placed on dorsal side of the skin and the negative electrode was attached 
to the electrode placed on the ventral side of the skin as shown in figure 8. 0.5 mA of current was 
applied for 10 minutes as shown in figure 5.  For first 3 trials, skin was collected after current 
application and left for 10 minutes and for last 3 trials, skin was collected after current application 
and left for 40 minutes. Each skin that was collected form trials was washed with distilled water 
in a beaker, cut into small pieces and immersed into 15 ml of water. The vials were covered with 
aluminum foil and left in a bio shaker for overnight, so that the pilocarpine formulation that has 
been penetrated into the superficial skin will come out into the water. 300 µl of solution was 
collected from each vial into the corresponding Eppendorf tube and 600 µl of basified Acetonitrile 
was added to each of the tube. The Eppendorf tubes were kept for centrifugation and the 
supernatant solutions were analyzed for pilocarpine using validated HPLC method.    
 
                               
 
Penetration Depth Profile 
Tape stripping procedure was performed to check the depth of penetration of pilocarpine. 
Tape stripping is a long established and minimally invasive technique to remove the stratum 
corneum for determining the depth of penetration of drug (48). This procedure involves repeated 
application and pulling off a pre-weighed adhesive tape on an area of skin surface where the drug 
Figure 5: Steps of Iontophoresis 
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is applied (48) and quantification of the drug per mg of epidermis from the tape strips by validated 
HPLC method.  
Tape stripping with the passive formulation 
 
Six trials were performed for final formulation. For first 3 trials, duration of study were 
10 minutes. Full thickness skin was collected at 10th minute of time point. The duration of study 
was 40 minutes for last 3 trials and full thickness skin was collected at 40th minute time point. 
The full thickness skin was sandwiched between donor and receiver compartment with the 
stratum corneum side facing the donor compartment. 17 µl/cm2 of final formulation was loaded 
into 1.74 cm2 area of donor compartment. Last 3 cells of 40th minute time point were placed in an 
incubator at a temperature of 40° C.  Each skin that was collected form trials was washed with 
distilled water in a beaker. For each piece of skin, three pre weighed adhesive tapes were used 
and each tape strip was repeatedly applied and pulled off for three times to remove the stratum 
corneum in the 1.76 cm2 area where the pilocarpine formulation was applied. After the 
procedure, weight of the tapes were noted again and first weight was subtracted from the second 
weight to get the weight of epidermis as shown in table 8. 
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Time Point Trial Number of 
Adhesive 
Tape 
1st Weight 
   (mg) 
2nd Weight 
    (mg) 
Weight of 
Epidermis 
     (mg) 
10 minute 1 1-3 434.18 435.52 1.34 
4-6 570.74 571.28 0.54 
7-9 556.66 556.89 0.23 
2 1-3 510.49 510.72 0.23 
4-6 551.87 551.17 0.3 
7-9 577.46 577.63 0.17 
3 1-3 556.46 546.95 0.49 
4-6 599.10 599.45 0.35 
7-9 531.75 532.06 0.31 
 
40 minute 
         
1 
1-3 531.97 533.63 1.66 
4-6 585.60 586.08 0.48 
7-9 535.31 535.81 0.50 
2 1-3 516.33 517.16 0.83 
4-6 528.27 528.95 0.68 
7-9 533.41 533.97 0.56 
3 1-3 524.23 524.83 0.60 
4-6 528.41 529.62 1.21 
7-9 503.23 504.58 1.35 
Table 7: Weight of adhesive tape and epidermis for passive formulation 
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Iontophoresis followed by tape stripping 
 
0.5% pilocarpine solution was used and six trials were performed for iontophoresis. 113 
µl/cm2 of 0.5% pilocarpine solution was applied on 1.76 cm2 area of the full thickness porcine 
skin. Full thickness skin was sandwiched between two 3M Red DotTM Adult Electrodes. The 
positive electrode was attached to the electrode placed on dorsal side of the skin. The negative 
electrode was attached to the electrode placed on the ventral side of the skin. 0.5 mA of current 
was applied for 5 minutes. For first 3 trials, skin was collected after current application and left 
for 10 minutes. For last 3 trials, skin was collected after current application and left for 40 
minutes. Each skin that was collected form trials was washed with distilled water in a beaker. For 
each piece of skin, pre weighed adhesive tape was repeatedly applied and pulled off for 9 times 
in the 1.76 cm2 area where the pilocarpine formulation was applied. After the procedure, weight 
of the tape was noted again and first weight was subtracted from the second weight to get the 
weight of epidermis as shown in table 9. 
 
Quantification of pilocarpine followed by tape stripping 
 
Each adhesive tape that was collected form trials of IVPT with passive formulation and 
iontophoresis with 0.5% pilocarpine solution were cut into small pieces and immersed into 15 ml 
of water. The vials were covered with aluminum foil and left in a bio shaker for overnight, so 
that the pilocarpine formulation will come out into the water. 1 ml of the solution was collected 
from each vial into corresponding Eppendorf. The Eppendorf tubes were kept for centrifugation 
and the supernatant solutions were analyzed for pilocarpine using validated HPLC method.    
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Time Point Porcine 
Skin 
Number of 
Adhesive 
Tape 
1st  Weight 
        (mg) 
2nd Weight 
    (mg) 
Weight of 
Epidermis 
     (mg) 
10 minute 1 1-3 495.56 498.66 3.1 
4-6 591.68 593.77 2.09 
7-9 579.33 580.24 0.91 
2 1-3 542.83 545.25 2.42 
4-6 543.15 544.21 1.06 
7-9 549.98 550.73 0.75 
3 1-3 554.14 556.76 2.62 
4-6 546.17 547.64 1.47 
7-9 520.22 521.23 1.01 
 
40 minute 
1 1-3 513.21 516.93 3.72 
4-6 557.49 559.36 1.87 
7-9 498.34 499.94 1.6 
2 1-3 554.19 557.28 3.09 
4-6 526.16 527.26 1.1 
7-9 527.92 528.57 0.65 
3 1-3 500.16 502.07 1.91 
4-6 513.16 514.36 1.2 
7-9 500.09 500.87 0.78 
Table 8: Weight of adhesive tape and epidermis for iontophoresis 
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Mechanistic Study 
Surface tension study 
 
                                   
 
 
The surface tension of all the formulations was measured by using Tensiometer (Biolin 
Scientific) as shown in Figure 6. All the measurements were performed at 20° C. The sample of 
the formulation was taken into the beaker and placed on the sample stage. The surface tension of 
the formulation was measured by using a platinum ring probe hanged on balance as shown in 
Figure 6. Platinum ring probe was immersed in the formulation and meniscus was formed 
pulling down the ring while the ring was raising from the formulation. The force applied on the 
meniscus was used to measure the surface tension. For each sample, it took five minutes to 
measure surface tension and the values were recorded twenty times.  
 
 
Figure 6: Tensiometer (Biolin Scientific) 
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Partitioning into octanol 
 
Partition coefficient is the ratio of concentration of unionized drug molecule in water and 
octanol phase at equilibrium. So the partition coefficient was determined for pilocarpine solution 
and the passive formulation containing octanol and water. 
In vivo Evaluation in Human Subjects 
 
The formulation was evaluated in healthy human volunteers to assess the ability of lead 
topical pilocarpine formulation to stimulate sweat production. Sweat secretions and its chloride 
concentration of sweat from small regions of arm was monitored in response of topical pilocarpine 
formulation. Twenty human subjects were assigned in the protocol. In this study, one circular area 
(12.2 cm in diameter) was marked on subject’s each of the forearms: one area on subject’s right 
forearm and one area on subject’s left forearm.  
The application site of subject’s right forearm was washed with distilled water and warm 
topical pilocarpine formulation (kept at 34°C) on the demarcated area was applied on subject’s 
skin. A pre-weighed filter paper was placed after the pilocarpine formulation was allowed to dry 
for 10 minutes. The forearm covering the demarcated area was wrapped with plastic wrap, heat 
bandage, paraffin film. After 30 minutes, filter paper was collected and weighed to determine the 
amount of sweat produced. At the end of the procedure, the application site was washed with soap 
and running water. 
Similarly, on the left forearm, same procedures will be performed using placebo solution 
instead of pilocarpine formulation. At the end of the study, treated areas will be washed with soap 
and water. 
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Chloride Concentration Measurement  
 
                                              
Figure 7: Chloride Analyzer (CIBA Corning 925 NSN 6630-01-137-8460) 
                
 
Chloride concentration of sweat was measured by using CIBA Corning 925 NSN 6630-01-
137-8460 chloride analyzer as shown in Figure 9. The chloride analyzer was calibrated with 20 µl 
of chloride standard.  
The chloride concentration of the sweat collected in the filter paper was determined by 
using the formula as mentioned below: 
Concentration of chloride= (20 X R * Density of sweat)/ weight of the sweat 
R: Reading on the analyzer, Density of sweat: 1.0047 g/ml  
                  
The beaker (provided with the device) and the petri dish were washed with combined 
buffer, and this combined buffer was conditioned by chloride analyzer to neutralize any pre-
existing chloride ions in the beaker and petri dish. Followed by the trial with topical pilocarpine 
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formulation, the filter paper was collected and chloride ions from the filter paper were eluted by 
immersing it in conditioned combined buffer in the petri dish for 10 to 15 seconds. And this 
combined buffer was titrated by chloride analyzer. 
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RESULTS AND DISCUSSION 
Screening of penetration enhancers 
Results 
 
Formulation 
Amount penetrated 
 after 10 minutes 
                      (µg) 
Amount penetrated 
 after 40 minutes 
        (µg) 
Control (Pilo 9%) 43.48 ± 6.94 58.07 ± 15.91 
Tr-5% 108.23 ± 46.70 89.27 ± 35.63 
Tr-10% 115.54 ± 54.08 82.58 ± 13.23 
P400-5% 79.81 ± 31.35 74.99 ± 13.04 
P400-10% 68.99 ± 0.57 80.20 ± 33.93 
P200-5% 69.81 ± 6.25 106.14 ± 22.42 
P200-10% 57.38 ± 47.65 69.54 ± 8.06 
M-2.5% 68.76 ± 8.97 73.43 ± 15.94 
M-5% 71.26 ± 19.82 78.92 ± 10.18 
SA-5% 106.29 ± 4.46 139.65 ± 34.39 
SA-10% 120.29 ± 27.54 158.97 ± 20.15 
Table 9: Amount of pilocarpine penetrated into the skin (individual enhancer) 
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Figure 8:Amount of pilocarpine nitrate penetrated into the skin at 10 minutes time   point 
(individual enhancer) 
 
 
 
Figure 9: Amount of pilocarpine nitrate penetrated into the skin at 40 minutes time  point  
(individual enhancer) 
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Discussion 
 
Penetration enhancers are the agents that promotes the penetration of the drug by 
decreasing the barrier resistance of the skin. So screening of the enhancers is an important 
introductory step for preparation of the formulation. Five individual enhancers with each of two 
concentrations were used during preparation of the formulation: Tr, P400, P200, Menthol and SA. 
P200 and P400 are the hydrating agent and menthol act as a cooling agent. As presented in table 
10, all the enhancers resulted in significant enhancement except for P200 10%. As shown in figure 
7 and figure 8, for Tr 10%, good penetration was observed after 10 minutes (115.54 ± 54.08 µg) 
but penetration was moderate after 40 minutes of time point (82.58 ± 13.23 µg). Amount of 
penetration was moderate both after 10 minutes (68.99 ± 0.57 µg) and 40 minutes (80.20 ± 33.93 
µg) for P400 5%. P200 5% showed better penetration after 40 minutes of time point (106.14 ± 
22.42 µg). Moderate penetration was observed both after 10 minutes (71.26 ± 19.82 µg) and 40 
minutes (78.82 ± 10.18 µg) for M 5%. SA 10% showed more penetration for both 10 minutes 
(120.29 ± 27.54 µg) and 40 minutes (158.97 ± 20.15 µg) time point compared to all other 
formulation with individual enhancer. Amount of penetration for SA 10% was statistically 
significantly higher compared to the control for both 10 minutes and 40 minutes time point. 
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Combination of enhancers 
Results 
 
Formulation 
Amount penetrated 
 after 10 minutes 
(µg) 
Amount penetrated  
  after 40 minutes 
 (µg) 
Control (Pilo 9%) 43.48 ± 6.94 58.07 ± 15.91 
P200+M 105.45 ± 41.58 140.60 ± 38.46 
P200+M+SA 145.91 ± 43.07 138.02 ± 23.33 
Table 10: Amount of pilocarpine nitrate penetrated into the skin (combination of enhancer) 
 
 
 
Figure 10: Amount of pilocarpine nitrate penetrated into the skin at 10 minutes time point 
(combination of enhancer) 
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Figure 11: Amount of pilocarpine nitrate penetrated into the skin at 40 minutes time point 
(combination of enhancer) 
  
 
 
Discussion 
 
Two formulations with combination of enhancers were prepared. The first formulation 
consists of P200 and Menthol. Though P200 and Menthol did not show significant amount of 
penetration, as several studies have shown the ability of these enhancers to improve the dermal 
drug delivery of several drugs. As shown in figure 9 and figure 10, formulation with combination 
of P200 and Menthol showed better penetration than the penetration observed by the formulation 
with respective individual enhancers. The second formulation is the combination of P200, Menthol 
and SA. As formulation with SA showed much better penetration compared to all other 
formulation with individual enhancer, SA was added to the second formulation to have a possible 
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0
30
60
90
120
150
180
Control (Pilo 9%) P200+M P200+M+SA
A
m
o
u
n
t 
 P
e
n
e
tr
at
e
d
(µ
g)
Formulation
40 min
 33 
formulation to minimize the irritation as they are cooling and hydrating agent respectively. 
Permeation study was done to observe if the ability of SA to enhance the penetration of pilocarpine 
is compromised because of hydrating and cooling agent. It appeared that the penetration ability of 
the formulation was improved while Menthol and P200 were added to SA. As shown in table 9 
and table 10, the formulation with P200, Menthol and SA showed great amount of penetration for 
both time points (145.91 ± 43.07 µg, 138.02 ± 23.33 µg) compared to all other formulations. As 
shown in table 10, the amount of penetration for the formulation with P200, Menthol and SA was 
better than control (43.48 ± 6.94 µg, 85.75 ± 62.96 µg) and formulation with P200 and M (105.45 
± 41.58 µg, 140.60 ± 38.46 µg). Therefore, the formulation with P200, Menthol and SA was 
considered to be the lead formulation. In addition to their ability to be supportive enhancers with 
salicylic acid, P200 is also a hydrating agent and Menthol is a cooling agent in the formulation. 
 
Drug retention study 
Results 
 
Name of the Study 
Formulation 
 
Amount 
penetrated 
after 10 minutes 
(µg) 
Amount 
penetrated after 
40 minutes 
 (µg) 
IVPT (42˚C) P200+M+SA 152.04 ± 52.23 210.27 ± 53.72 
Iontophoresis Pilocarpine Solution 97.05 ± 27.93 140.56 ± 88.66 
Table 11: Total amount of pilocarpine nitrate present in the skin Followed by passive 
delivery and iontophoresis 
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Figure 12: Total amount of pilocarpine nitrate present in the skin after 10 minutes followed 
by passive delivery and iontophoresis 
 
 
Figure 13: Total amount of pilocarpine nitrate penetrated in the skin after 40 minutes 
followed by passive delivery and iontophoresis 
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Discussion 
 
The passive formulation with P200, Menthol and SA performed well and enhance the 
delivery of large amount of pilocarpine. IVPT with passive formulation and iontophoresis with 
0.5% of pilocarpine solution were performed to prove that the passive formulation performs as 
good and efficient as the iontophoresis. As shown in table 11, the total amount of pilocarpine 
nitrate present in skin followed IVPT with passive formulation was compared with that of 
iontophoresis with 0.5% pilocarpine solution. 
As shown in figure 11 and figure 12, the total amount of pilocarpine nitrate present in skin 
followed IVPT with passive formulation is much higher than that of iontophoresis with 0.5% 
pilocarpine solution for both 10 and 40 minutes time point. As shown in table 11, amount of 
penetrated drug for passive formulation is 152.04 µg at 10 minutes time point and 210.27 µg at 40 
minutes time point. However, for iontophoresis with 0.5% pilocarpine solution, the amount of 
penetrated drug is 97.05 µg at 10 minutes time point and 140.56 µg at 40 minutes time point. 
 
Effect of Temperature on Penetration 
Results 
 
Formulation Penetration after 10 minutes 
 (µg) 
Penetration after 40 minutes 
 (µg) 
P200+M+SA (25 °C) 145.91 ± 43.07 138.02 ± 23.33 
P200+M+SA (40 °C) 152.04 ± 52.23 210.27 ± 53.72 
          Table 12: Effect of temperature on amount of penetration of pilocarpine nitrate 
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Figure 14: Effect of temperature on amount of penetration of pilocarpine nitrate at 10 
minutes time point 
 
 
Figure 15: Effect of temperature on amount of penetration of pilocarpine nitrate at 40 
minutes time point 
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Discussion 
 
As the final objective is to apply the passive formulation for 10 minutes and wrap the 
application site with heat bandage for next 30 minutes; it was observed if the amount of penetration 
is increased due to application of heat. So, one penetration study was performed with passive 
formulation where last three trials were kept in the incubator at 43°C and in another penetration 
study was performed at 25° C. As shown in table 11, for the penetration study at 40° C, the amount 
of penetration is relatively higher than the one was performed at 25° C for both time point. 
 
Penetration Depth profile 
Results 
 
Formulation Tape Stripping 
Amount of drug in 
epidermis after 10 
minutes 
(µg/mg) 
Amount of drug in 
epidermis after 40 
minutes 
(µg/mg) 
P200+M+SA 
1-3 30.93 ± 20.25 20.38 ± 13.92 
4-6 22.50 ± 10.10 16.16 ± 7.81 
7-9 25.03 ± 7.77 16.78 ± 11.42 
Total (1-9) 138.09 ± 64.66 93.85 ± 30.83 
Iontophoresis 
1-3 4.15 ± 1.29 1.40 ± 0.67 
4-6 3.67 ± 1.33 1.98 ± 0.41 
7-9 5.50 ± 1.95 4.00 ± 0.88 
Total (1-9) 23.44 ± 6.13 12.98 ± 0.85 
Table 13: Total amount of drug present in the tape strip followed by IVPT and 
iontophoresis 
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Figure 16: Total amount of drug present in the tape strip after 10 minutes followed by passive 
delivery and iontophoresis 
 
Figure 17: Total amount of drug present in the tape strip after 40 minutes followed by passive 
delivery and iontophoresis 
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Discussion 
 
Though it is shown in table 11, more amount of pilocarpine was getting penetrated during 
IVPT with passive formulation compared to the iontophoresis; the determination of the depth of 
penetration of pilocarpine into the epidermis is also important. Therefore, the tape stripping 
procedure was performed on 1.76 cm2 area of porcine skin followed by the IVPT with passive 
formulation and the iontophoresis with 0.5% pilocarpine solution.  
As shown in table 12, large amount of drug was present in tape strips (78.46 µg/mg) at 10 
minutes time point for passive formulation. On the other hand, for pilocarpine iontophoresis, very 
small amount of drug was present in the tape strips at the same time point (13.32 µg/mg). For 40 
minutes time point, the amount of drug presented in tape strips was  significantly  higher (53.32 
µg/mg) in case of passive formulation compared to that of the iontophoresis (7.38 µg/mg). 
 
Mechanistic Study 
Surface tension study 
Result 
 
Formulation 
Surface Tension 
(mN/m) 
 
Control (Pilo 9%) 71.74 ± 0.19 
P200+M+SA 28.25 ± 0.03 
             Table 14: Surface tension of control and passive formulation 
                       
  
 
 40 
 
 
Figure 18: : Surface tension of control and passive formulation 
                        
 
Discussion 
 
Surface tension is the cohesive attraction between liquid molecule that allow the liquid to 
resist the external force and to maintain the elastic tendency of liquid surface. Surface tension of 
the passive formulation (28.25 ± 0.03 mN/m) is half of that of the control (71.74 ± 0.19 mN/M). 
Convective transport is the criteria that depends on the surface tension of the liquid. The lower 
the surface tension, the better the convective transport and the better ability of liquid to penetrate 
into pores. As the passive formulation (P200+M+SA) has lower surface tension, it can be 
concluded that the amount of penetration that was observed in first 10 minutes was significantly 
contributed by convective transport. 
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Ion pairing 
 
Ion pairing is the partial bonding between a positive and a negative ion driven by electrostatic 
force of attraction between them and this partial association mostly occurs in concentrated solution 
of electrolytes. In high concentration of sodium chloride solution, the positively charged sodium 
ion associates with negatively charged chloride ion and thereby makes an ion pair (49). 
Hydrophilic or ionized drugs are relatively less permeable through lipid layer of stratum 
corneum which leads to poor trans-epidermal bioavailability. Incorporation of penetration 
enhancers has long been used to improve the permeability of the ionized drug. Moreover, ion pair 
has also been used to increases the lipophilisation of ionic drugs thereby increase the skin 
permeability of ionized molecule (50).  It has been used to promote the percutaneous penetration 
of ionized molecule using artificial and biological membrane (51).  
Permeation of diclofenac is increased by ion pair formation between negatively charged 
diclofenac and positively charged alkylamine or benzylamine. Ion pair between diclofenac and n-
hexylamine improves the permeation of diclofenac by 7.3 folds (52). Ion pairing is also used as a 
tool to improve the transdermal delivery of ionized drugs such as salicylic acid (51, 50). Skin 
permeability of salicylic acid is increased by forming an ion pair between anionic salicylic acid 
and cationic alkyl amines.It was assumed that anionic and hydrophilic SA will pair with positively 
charged hydrophilic pilocarpine and will form unionized lipophilic SA-pilocarpine ion pair. The 
unionized SA- pilocarpine ion pair facilitates the penetration of pilocarpine into the skin. To prove 
this hypothesis, partition coefficient study was performed. 
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Results 
 
 
 
 
 
 
 
 
Discussion 
 
Partition coefficient is the ratio of concentration of unionized drug molecule in octanol 
and water phase at equilibrium. During partition coefficient study, octanol phase is the 
representative of biological membrane lipid. As SA is forming an ion pair with pilocarpine, the 
unionized lipophilic SA-pilocarpine ion pair was hypothesized to partition into octanol 
(represents stratum corneum lipid phase) compared to its hydrophilic counterpart. It was 
observed if ion pairing is happening or not; if it is happening more partitioning of pilocarpine 
was expected in octanol phase compared to aqueous phase.  
 
Solution Amount in octanol 
phase (µg/ml) 
Pilocarpine solution (used in 
iontophoresis) 
1.07 
Passive formulation 1.72 
Table 15: Partitioning of pilocarpine in octanol phase for passive formulation and 
iontophoresis 
Salicylateˉ 
(Hydrophilic) 
 
Pilocarpine+ 
(Hydrophilic) 
 
Pilocarpine – Salicylic 
acid (Lipophilic) 
 
Figure 19: Formation of Pilocarpine -Salicylic acid ion pair Partitioning into Octanol 
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In vivo Evaluation in Human Volunteers 
Results 
 
Subject Formulation 
Initial Wt 
filter paper 
Final Wt 
filter paper 
Sweat 
collected 
Reading Cl Conc. 
1 
Test 368.8 421.9 53.1 16 6.04 
Control 374.8 381.6 6.8 0 0.00 
2 
Test 364.5 409 44.5 17 7.65 
Control 365 392.9 27.9 4 2.87 
3 
Test 364.8 417 52.2 40 15.35 
Control 363.3 403 39.7 18 9.08 
4 
Test 381.9 430 48.1 41 17.08 
Control 373.3 388.5 15.2 5 6.59 
5 
Test 374.8 442.3 67.5 37 10.98 
Control 372 383.8 11.8 1 1.70 
6 
Test 372.5 441 68.5 39 11.41 
Control 380.5 413 32.5 7 4.32 
7 
Test 377.8 459.9 82.1 22 5.37 
Control 371.1 393.8 22.7 0 0.00 
8 
Test 370.2 465 94.8 24 5.07 
Control 375.3 392.5 17.2 0 0.00 
9 
Test 363.3 451.7 88.4 30 6.80 
Control 371.5 401.5 30 3 2.00 
10 
Test 369.6 469 99.4 38 7.66 
Control 370.3 391 20.7 1 0.97 
11 
Test 365 477.4 112.4 106 18.89 
Control 361.9 371.9 10 0 0.00 
12 
Test 373.4 455.1 81.7 64 15.69 
Control 361.9 368.9 7 0 0.00 
13 
Test 362.4 464.1 101.7 39 7.68 
Control 373.9 394 20.1 1 1.00 
14 
Test 372 454.2 82.2 22 5.36 
Control 371 376.9 5.9 0 0.00 
15 
Test 373.3 472.6 99.3 109 21.99 
Control 366.8 380.8 14 2 2.86 
16 
Test 375 456.8 81.8 69 16.90 
Control 355.9 359.9 4 0 0.00 
17 
Test 371.5 440.5 69 86 24.97 
Control 370 386.4 16.4 5 6.11 
18 
Test 366.6 442.2 75.6 62 16.43 
Control 366.4 377.1 10.7 1 1.87 
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19 
Test 362.4 428.1 65.7 19 5.79 
Control 363.4 373.7 10.3 1 1.95 
20 
Test 356.4 433.9 77.5 24 6.20 
Control 371 383.1 12.1 1 1.66 
Table 16: Results of clinical study (n=20) 
     
Formulation 
Sweat Collected 
(mg) 
Chloride Concentration 
(mmol/l) 
Test 77.28 ± 18.97* 11.67 ± 6.22 
Control 16.75 ± 9.71  
Table 17: Average weight of collected sweat and average chloride concentration 
            
Discussion 
 
Followed by the clinical study, filter paper was collected and chloride concentration was 
measured using chloride analyzer (CIBA Corning). As shown in table 17, average weight of the 
sweat for the test (passive formulation) was statistically significantly higher compared to that of 
the control. Some sweat was produced for control. However, the amount of the sweat was not 
enough to determine the chloride concentration. Though heating pad was applied for both test and 
control, very small amount of sweat was produced for control. So it was observed that the amount 
of sweat produced for test formulation was significantly contributed to passive formulation. 
Following formula was used to determine the chloride concentration 
 Concentration of chloride= (20R * Density of sweat)/ weight of the sweat 
R= Reading from chloride analyzer 
Density of the sweat= 1.00176 gm/ml 
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POTENTIAL APPLICATION OF SWEAT COLLECTION USING PASSIVE 
FORMULATION 
 
Sweat analysis can be used as an important diagnostic tool for lots of diseases such as cystic 
fibrosis, diabetes, lung cancer. In cystic fibrosis, qualitative and quantitative sweat analysis are 
usually performed for chloride concentration in sweat. Chloride concentration of ≥60 mmol per 
liter indicates that the patient is consistent with cystic fibrosis. And the chloride concentration of 
30-60 mmol per liter of sweat is an indication of borderline cystic fibrosis (37). 
Moreover, sweat analysis can also be used as diagnostic technique for diabetes as the 
diabetic biomarkers such as correlation between the blood glucose and the sweat glucose, change 
in rate of sweating (53, 54) and the composition of sweat (53, 55) can be determined by sweat 
analysis.  In this test, foot sweat is collected in a patch and is analyzed based on color change of 
the patch from blue to pink due to addition of 6 molecules of water into it (53, 56). 
Furthermore, sweat sample is also used as a screening tool for lung cancer. In this method, 
metabolites of sweat are analyzed to discriminate between patient with lung cancer and healthy 
individuals (53).  
Sweat also plays a significant role in the field of genomics and proteomics. Sweat contains 
an amino acid called dermcidin (DCD) that is also a tumor marker in breast carcinoma. Elevated 
level of DCD and overexpressed receptor for DCD have been observed in patient of breast 
carcinoma (53). Drug contents and ethanol can be detected by sweat analysis. Qualitative detection 
of drugs from the sweat sample is done by immunochromatographic test and patch technology. 
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Immunochromatographic test is applicable for the drugs that are ingested within 24 hours 
and this method requires collection of sweat sample for single time point to detect individual under 
the influence of drug (53). And the drug ingested within 168 hours can be detected by patch 
technology. In this method, sweat sample is collected for single time point to follow up the 
previous drug abusers who are under abstinence treatment (53). Moreover, quantitative detection 
of drugs such as opiates, buprenorphine, cocaine, amphetamines, cannabinoids is done from the 
sweat sample (53, 57). Moreover, ethanol can also be detected by the sweat analysis which can be 
useful as a valuable tool in alcohol abuse (53, 58). 
 47 
CONCLUSION 
 
Passive formulation method can be used as an alternative to iontophoresis as the new 
diagnostic method can overcome the limitations involved in the current one. Passive formulation 
can increase the patient compliance as it does not involve the application of current to deliver the 
pilocarpine. Moreover, the menthol and P200, which are the ingredient of the passive 
formulation gives the cooling sensation and maintain the hydration of the skin. It was observed 
form the IVPT that the passive formulation can enhance the delivery of more amount of 
pilocarpine into the skin compared to iontophoresis. In addition, tape stripping method confirms 
that new alternate diagnostic method can deliver the more pilocarpine compared to iontophoresis 
to the deepest layer of epidermis without any driving force such as application of current. 
Moreover, as very small amount of pilocarpine (1 mg) is applied on the skin, it would not go far 
enough down to reach the systemic circulation. So there less chances of systemic side effects or 
toxicity. Based on these observations, it can be inferred that passive formulation is an efficient, 
alternative method to iontophoresis. 
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